Pharmaceutical company Crossject (Euronext Growth Paris:ALCJ) announced on Thursday that its ZENEO needle-free auto-injector has achieved consistent intramuscular injection depth comparable to a conventional 30-mm needle in a recent Magnetic Resonance Imaging (MRI) study.

In a trial involving 50 healthy subjects, ZENEO delivered a mean injection depth of 34 mm on bare skin and 28 mm through clothing, both within the clinical range for intramuscular administration. These depths exceed those of most commercially available needle-based auto-injectors, which typically feature needle lengths between 11 and 25 mm.

The study demonstrated reliable dose delivery and pathway accuracy, reinforcing ZENEO's potential use in emergency and rescue scenarios. Local reactions were mild and consistent with traditional intramuscular injections.

The results also align with previous clinical data showing bioequivalence between ZENEO-administered midazolam and syringe-based delivery using a 30-mm needle. Crossject highlighted these findings as key to advancing regulatory efforts and commercial strategy for ZEPIZURE, its lead emergency treatment for epilepsy crises.

ZENEO's needle-free design offers an added safety advantage by eliminating usage errors and injection-related injuries. These findings further position the device as a competitive alternative in the auto-injector market.